Risk of venous thromboembolism

Treating patients with the recombinant monoclonal antibody bevacizumab carries a significant risk of venous thromboembolism (VTE), a meta-analysis has shown. Researchers included data on 7,956 patients with a variety of advanced solid tumours from 15 randomised controlled trials in their analysis. Among patients receiving the angiogenesis inhibitor, the incidence of all-grade and high-grade VTE was 11.9 and 6.3 per cent, respectively. Patients' overall risk of VTE was 33 per cent higher than for controls. The researchers found that VTE risk was similarly increased for low-dose bevacizumab (2.5 mg/kg per week; RR 1.31, p 0.007) and high-dose treatment (5 mg/kg per week; RR 1.31, p =.04).

Nalluri SR, Chu D, Keresztes R et al. JAMA 2008;300(19):2277-85

Originally published in the November 2008 edition of MIMS Oncology & Palliative Care.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs